Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 771

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 771
---
 2024, the Company recorded $2 (2023 - $2) related to the dividends paid to Valent. The dividends have been recorded as a direct increase in accumulated deficit. On February 13, 2024, the Company sent an Opt-OutNotice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title and interest in and to the patents for VAL-083to Valent. As a result, the Company granted Valent a non-exclusive,fully-paid, royalty-free, perpetual, worldwide and non-transferablelicense, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization of VAL-083equal to 5% of Valent Net Sales (as defined in the Valent Assignment Agreement). Related party payables As of September 30, 2024, there is an aggregate amount of $50 (June 30, 2024 - $52) payable to the Company’s officers and directors for fees, expenses, and other liabilities. F-39

8 Stockholders’ equity Preferred stock Series C Preferred Stock

|                                                        |     | Series C Preferred Stock |         |   |     |                |        |   |
|                                                        |     | Number                   
 of shares                |         |   |     | $              
 (in thousands) |        |   |
| Balance - June 30, 2024                                |     |                          |  13,668 |   |     |                |  9,973 |   |
| Conversion of Series C Preferred stock to common stock |     |                          | (13,668 | ) |     |                | (9,973 | ) |
| Balance - September 30, 2024                           |     |                          |       — |   |     |                |      — |   |

In August 2020, the Company issued 25,028 shares of Series C Convertible Preferred Stock (the “Series C Preferred Stock”) in three separate closings of a private placement (Series C-1, C-2,and C-3).Each share of Series C Preferred Stock was issued at a purchase price of $1,000 per share and is convertible into shares of common stock based on the respective conversion prices which were determined at the closing of each round of the private placement. The conversion prices for the Series C-1Preferred Stock, Series C-2Preferred Stock, and the Series C-3Preferred Stock were $2,030.00, $2,124.50, and $2,012